LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN

Various endocrine-related tumours contain large numbers of high-affinity somatostatin receptors. 123I-labelled tyr-3-octreotide (tyr-3-SMS 201-995, a synthetic derivative of somatostatin) was used to localise such tumours in vivo with a gamma-camera. Positive scans were obtained for two meningiomas, two gastrinomas, and one carcinoid; negative scans were obtained for one insulinoma (in which unlabelled octreotide had no effect on insulin levels), one phaeochromocytoma, one adrenal carcinoma (octreotide had no effect on cortisol levels), and three medullary thyroid carcinomas (octreotide had no effect on calcitonin levels). Thus radioiodinated tyr-3-octreotide can label somatostatin receptors in endocrine-related tumours in vivo and can therefore be used for tumour localisation.

[1]  S. Lamberts,et al.  Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. , 1985, The New England journal of medicine.

[2]  J. Reubi,et al.  Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. , 1987, The Journal of clinical endocrinology and metabolism.

[3]  J. Klijn,et al.  Somatostatin receptors in human endocrine tumors. , 1987, Cancer research.

[4]  R. Jensen,et al.  Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. , 1985, The New England journal of medicine.

[5]  J. Reubi.  A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth. , 1985, Acta endocrinologica.

[6]  J. Foekens,et al.  High incidence of somatostatin receptors in human meningiomas: biochemical characterization. , 1986, The Journal of clinical endocrinology and metabolism.

[7]  J. Reubi,et al.  Studies on the mechanism of action of the inhibitory effect of the somatostatin analog SMS 201-995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumor 7315a. , 1986, Endocrinology.

[8]  S. Lamberts,et al.  Potential role of somatostatin analogues in the treatment of cancer , 1987, European journal of clinical investigation.

[9]  J. Reubi.  New specific radioligand for one subpopulation of brain somatostatin receptors. , 1985, Life sciences.

[10]  J. Reubi,et al.  High density of somatostatin receptors in pituitary tumors from acromegalic patients. , 1984, The Journal of clinical endocrinology and metabolism.

[11]  L. Kvols,et al.  Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. , 1986, The New England journal of medicine.

[12]  P. Marbach,et al.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. , 1982, Life sciences.

[13]  S. Lamberts,et al.  The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. , 1985, The Journal of clinical endocrinology and metabolism.

[14]  A. Bogdén,et al.  In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue. , 1988, Biochemical and biophysical research communications.